Equities research analysts at Craig Hallum initiated coverage on shares of Guardant Health (NASDAQ:GH - Get Free Report) in a research report issued to clients and investors on Wednesday, MarketBeat Ratings reports. The firm set a "buy" rating and a $28.00 price target on the stock. Craig Hallum's price objective would indicate a potential upside of 54.70% from the stock's previous close.
A number of other equities research analysts have also weighed in on the company. Guggenheim reaffirmed a "neutral" rating on shares of Guardant Health in a report on Friday, April 5th. Canaccord Genuity Group reduced their price target on shares of Guardant Health from $50.00 to $45.00 and set a "buy" rating for the company in a research report on Friday, February 23rd. The Goldman Sachs Group reduced their price target on shares of Guardant Health from $32.00 to $28.00 and set a "buy" rating for the company in a research report on Monday, April 15th. JPMorgan Chase & Co. reduced their price target on shares of Guardant Health from $60.00 to $45.00 and set an "overweight" rating for the company in a research report on Friday, February 23rd. Finally, Piper Sandler reduced their price target on shares of Guardant Health from $40.00 to $30.00 and set an "overweight" rating for the company in a research report on Monday, February 26th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, Guardant Health currently has an average rating of "Moderate Buy" and an average price target of $39.27.
Read Our Latest Stock Report on GH
Guardant Health Stock Performance
Shares of GH traded up $0.76 during mid-day trading on Wednesday, reaching $18.10. 1,796,030 shares of the company's stock were exchanged, compared to its average volume of 1,894,619. The business's fifty day simple moving average is $19.02 and its 200-day simple moving average is $23.03. The stock has a market capitalization of $2.20 billion, a PE ratio of -4.23 and a beta of 0.87. Guardant Health has a 52-week low of $15.81 and a 52-week high of $41.06. The company has a debt-to-equity ratio of 7.18, a current ratio of 6.54 and a quick ratio of 6.24.
Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.93) by ($0.65). Guardant Health had a negative return on equity of 301.94% and a negative net margin of 85.02%. The company had revenue of $155.05 million for the quarter, compared to analysts' expectations of $151.71 million. On average, equities research analysts expect that Guardant Health will post -3.49 earnings per share for the current year.
Insider Buying and Selling
In other Guardant Health news, insider Kumud Kalia purchased 2,187 shares of the firm's stock in a transaction that occurred on Monday, March 18th. The stock was purchased at an average cost of $17.82 per share, with a total value of $38,972.34. Following the transaction, the insider now owns 12,722 shares in the company, valued at $226,706.04. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.20% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Guardant Health
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC purchased a new position in Guardant Health in the 1st quarter valued at about $273,000. Vanguard Group Inc. raised its stake in shares of Guardant Health by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 11,130,654 shares of the company's stock valued at $301,084,000 after purchasing an additional 180,424 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Guardant Health by 24.1% in the 4th quarter. Wellington Management Group LLP now owns 834,084 shares of the company's stock valued at $22,562,000 after purchasing an additional 161,986 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Guardant Health in the 4th quarter valued at about $233,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Guardant Health in the 4th quarter valued at about $3,868,000. 92.60% of the stock is owned by hedge funds and other institutional investors.
Guardant Health Company Profile
(
Get Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Further Reading
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
